Drug Interactions in Clinical Practice: Identification, Prevention, and Management: A Narrative Review Depth Study

Majed Saleh M Aljohani

Pharmacy Technician, Islamic University of Madinah, Madinah, Saudi Arabia

Email id: majed@iu.edu.sa

Abstract:

Background: Drug interactions are a frequent and sometimes preventable cause of medication-related harm. They can make a medicine more toxic, weaken its therapeutic effect, or in carefully selected regimens be used to improve treatment. Whether an interaction matters clinically depends on the medicines involved, their doses and duration, the patient's circumstances, and the availability of monitoring. Objective: This review discusses how clinically important drug interactions occur, how they can be recognized, and what clinicians can do to prevent or manage them in everyday practice. Methods: The review draws on regulatory guidance, medication-safety recommendations, clinical reviews, and peer-reviewed literature covering drug–drug, drug–food, drug–supplement, and drug–disease interactions. It is a narrative synthesis, not a systematic review; no formal risk-of-bias assessment or meta-analysis was performed. Discussion: Interactions can alter a medicine's absorption, distribution, metabolism, or excretion (pharmacokinetic effects), or change its effect on the body without changing its concentration (pharmacodynamic effects). Examples encountered in practice include bleeding associated with anticoagulants, excessive sedation, QT prolongation, electrolyte abnormalities, and treatment failure after enzyme induction. Extra care is often needed for older adults, people with kidney or liver impairment, patients living with several conditions, and anyone using multiple prescribers or non-prescription products. Electronic checkers are useful, but each alert still needs to be judged in the context of the individual patient. Accurate medication reconciliation, risk-based monitoring, counselling, and documentation remain essential. Conclusion: A practical approach starts with an accurate medication history, followed by verification of the suspected interaction and assessment of the patient's risk. Clinicians can then decide whether to avoid the combination or manage it with an alternative, dose adjustment, or monitoring, and communicate the plan clearly. Pharmacists and multidisciplinary teams can make this process more reliable, especially when patients move between care settings.

Keywords: Drug interactions; Medication safety; Medication reconciliation; Clinical pharmacy; Pharmacokinetics; Pharmacodynamics; Polypharmacy.

INTRODUCTION

Patients often need more than one medicine to manage an acute illness or a long-term condition. Such combinations can be appropriate, but they also create the possibility that one medicine, food, supplement, or illness will change the effect of another. The consequences range from an adverse reaction or reduced treatment benefit to a more complicated diagnosis or hospital admission. Some interactions are deliberately used for example, to boost exposure to a medicine in selected antiviral regimens whereas others can and should be avoided [1,2]. Medicine count alone does not tell the whole story. Someone taking several appropriate medicines with reliable follow-up may face less risk than a person taking only two medicines that have a serious interaction and a narrow safety margin. Dose, timing, duration, kidney and liver function, genetic variation, adherence, acute illness, and available alternatives all influence the outcome. Interaction databases can flag a possible problem, but clinicians still need to decide whether it is meaningful for that particular patient [1,3].

Medication safety becomes more challenging as people live longer with several chronic conditions and use increasingly complex regimens. The World Health Organization's Medication Without Harm initiative identifies polypharmacy, high-risk situations, and transitions of care as priorities for reducing preventable harm [4]. Interaction review therefore needs to continue beyond the initial prescription. It should be repeated when a medicine is started, stopped, or adjusted, and when diet, organ function, or the patient's clinical condition changes. This review focuses on the mechanisms behind drug interactions, practical ways to identify them, examples that matter in clinical care, and options for prevention and management. The aim is to help clinicians and pharmacists respond proportionately instead of treating every electronic alert as

equally serious.

2. REVIEW APPROACH

This narrative review draws on peer-reviewed clinical literature, regulatory resources, professional guidance, and medication-safety publications identified through focused searches of biomedical literature and official websites. Priority was given to guidance on enzyme and transporter interactions, medication review, older adults, clinical decision support, and common high-risk combinations. References were selected for clinical relevance and authority; the review was not designed as a systematic review, and search dates, duplicate screening, and formal evidence grading were not undertaken. Recommendations should be interpreted alongside current product information, local protocols, and patient-specific judgement.

3. DEFINITIONS AND CLASSIFICATION

A drug interaction occurs when another medicine, food, drink, supplement, environmental exposure, or health condition changes how a treatment works. This may increase or decrease drug exposure, strengthen or weaken the intended effect, or produce a new adverse effect. Interactions can be grouped by the substances involved, their mechanism, their clinical consequences, or the action needed to manage them [1,5]. Drug–drug interactions involve two or more medicines. Drug–food interactions occur when food or beverages alter absorption, metabolism, or effect; grapefruit products, for example, can inhibit intestinal CYP3A activity for certain susceptible medicines. Drug–supplement interactions involve herbal products, vitamins, minerals, or other non-prescription preparations. Drug–disease interactions occur when a medicine worsens an existing condition or when the disease changes drug handling. These categories overlap: a patient with chronic kidney disease who takes a renin–angiotensin system inhibitor and a potassium supplement may face a combined drug–drug and drug–disease risk.

A potential interaction is not automatically a clinically important one. Some combinations are contraindicated because the risk of serious harm cannot be managed reliably. Others can be used with dose adjustment, carefully timed administration, laboratory tests, or clinical observation. Some have little effect at usual doses, and a few are deliberately used to improve treatment. FDA classifications of CYP enzyme inhibitors and inducers help standardise drug-development assessments, but decisions in practice must also account for pharmacodynamic effects and the patient's individual risks [6].

Table 1. Practical classification of drug interactions.

Classification	Mechanism	Potential consequence	Typical response
Pharmacokinetic	Changes absorption, distribution, metabolism, or excretion	Altered concentration, toxicity, or loss of efficacy	Avoid, adjust dose, separate administration, or monitor exposure
Pharmacodynamic	Additive, synergistic, or opposing effects at receptors or organ systems	Bleeding, sedation, hypotension, arrhythmia, or reduced effect	Avoid high-risk combinations or monitor relevant clinical endpoints
Drug–food / supplement	Changes in absorption, enzymes, transporters, or physiological response	Variable exposure or adverse effects	Clarify product and diet history; give specific instructions
Drug–disease	Medicine worsens a condition or disease changes drug handling	Decompensation or increased toxicity	Choose an alternative or adapt dose and monitoring
Intentional interaction	Predictable interaction used to improve efficacy or exposure	Therapeutic benefit when controlled	Follow protocol and monitor for known risks

4. MECHANISMS OF DRUG INTERACTIONS

4.1 Pharmacokinetic interactions

Pharmacokinetic interactions change the amount of a medicine reaching the circulation or how quickly it is cleared. The consequences depend on how much the medicine relies on the affected pathway, the size of the change, and its therapeutic index. Even a modest rise in concentration can matter for a

medicine with a narrow safety margin, while the same change may have little effect on a drug with a wider therapeutic window [1,6].

4.1.1 Absorption

Absorption interactions may result from chelation, binding, altered gastric pH, changes in gastrointestinal motility, or effects on transporters. Calcium, iron, magnesium, and aluminium can bind certain antibiotics, including tetracyclines and fluoroquinolones, reducing absorption. The practical response is often to separate doses according to the specific product information; a universal interval should not be assumed because the required spacing differs by medicine and formulation. Antacids and acid-suppressing agents may also alter the absorption of pH-dependent medicines. Food can delay, increase, or reduce absorption, so instructions such as taking with food or on an empty stomach should be drug-specific.

4.1.2 Distribution and protein binding

Displacement from plasma proteins is often discussed as a mechanism, but a transient increase in the unbound fraction does not automatically cause clinically important toxicity. The unbound drug may distribute or be eliminated more rapidly, restoring equilibrium. Greater concern arises when displacement is combined with impaired clearance, saturable elimination, or a narrow therapeutic index. Clinicians should avoid assuming that protein-binding displacement alone explains a clinical event without supporting evidence.

4.1.3 Metabolism: enzyme inhibition and induction

Cytochrome P450 enzymes, particularly CYP3A4/5, CYP2C9, CYP2C19, CYP2D6, and CYP1A2, metabolise many commonly prescribed medicines. Inhibition can reduce metabolism and increase exposure to a substrate, potentially causing toxicity. Induction increases enzyme expression or activity and can lower concentrations, leading to treatment failure. Inhibition may appear relatively quickly, whereas induction often develops and resolves over several days or longer as enzyme activity changes. The FDA provides examples of substrates, inhibitors, and inducers, while the ICH M12 guideline harmonises approaches to evaluating enzyme- and transporter-mediated interactions [6,7].

For example, a strong CYP3A inhibitor may increase exposure to a susceptible statin, increasing myopathy risk; the exact action depends on the statin, inhibitor, dose, and product label. Rifampicin is a clinically important inducer and can reduce exposure to numerous medicines, including some hormonal contraceptives, immunosuppressants, and anticoagulants. St John's wort can also induce metabolic pathways and transporters, making it important to ask about herbal products. The direction and size of an interaction cannot be generalised across all members of a drug class.

4.1.4 Transporters and renal elimination

Transport proteins such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptides can influence absorption, tissue distribution, and elimination. Inhibition of a transporter may increase systemic exposure or tissue concentrations, while induction may reduce exposure. Renal interactions can occur through changes in glomerular filtration, tubular secretion, urine pH, or renal haemodynamics. Combining medicines that impair kidney function or alter potassium handling can create clinically important toxicity even without a classic metabolic interaction.

4.2 Pharmacodynamic interactions

Pharmacodynamic interactions change the effect of medicines without necessarily changing their concentrations. Additive effects occur when two agents act in the same direction; synergistic effects exceed what would be expected from simple addition; antagonistic effects reduce one another's effect. These interactions may be easier to recognise clinically but can still be difficult to predict in people with multiple diseases. Examples include increased bleeding with anticoagulants and antiplatelet agents; respiratory depression with opioids and benzodiazepines; hyperkalaemia with combinations that increase potassium; hypotension with multiple blood-pressure-lowering medicines; and QT prolongation with selected antiarrhythmics, antimicrobials, antipsychotics, and other agents. Serotonergic medicines may precipitate serotonin toxicity when combined in high-risk circumstances. These combinations are not all universally prohibited: the decision depends on indication, dose, alternatives, and the monitoring available [6,7].

4.3 Combined and indirect interactions

Real-world harm often arises from several modest effects acting together. A patient taking a diuretic may develop hypokalaemia; an added QT-prolonging drug then creates greater arrhythmic risk. An infection may reduce oral intake and renal function, increasing the exposure to a renally cleared medicine. Alcohol can amplify sedation from central nervous system depressants. These examples show why medication

review should include laboratory values, symptoms, hydration, diet, alcohol, and recent illness not merely a list of drug pairs [8].

5. IDENTIFICATION AND ASSESSMENT IN CLINICAL PRACTICE

5.1 Obtain a complete and reliable medication history

The first step is to establish what the patient actually uses. The list should include prescribed medicines, as-needed products, over-the-counter analgesics and cold remedies, vitamins, minerals, herbal products, traditional medicines, topical preparations, inhalers, eye drops, injections, recreational substances, alcohol, and relevant foods. Record dose, route, frequency, indication, recent changes, and the source of each prescription. Ask specifically about medicines obtained from multiple clinics, online sources, pharmacies, or family members. Patients may not consider supplements or short courses to be medicines, so open-ended questions are more effective than asking only whether they take other drugs [8,9]. Medication reconciliation compares the best available medication history with current orders at admission, transfer, and discharge. It identifies omissions, duplications, unintended changes, and discrepancies that can lead to interaction risk. Reconciliation should be a clinical process, not a clerical exercise: the team should resolve differences, document intentional changes, and communicate the updated list to the patient and next care provider [8,9].

5.2 Screen with a clinical question in mind

Electronic interaction databases and prescribing systems are useful for screening, especially when a medicine is initiated or its dose changes. However, databases vary in scope, severity categories, evidence sources, and suggested actions. A software warning should prompt assessment rather than automatically determine care. Confirm the exact products and formulations, the proposed doses, whether both agents are actually being taken, the expected onset, the likely magnitude, and the consequences if the interaction occurs. Consult current prescribing information and a trusted interaction resource when the result is uncertain. A useful assessment asks: Is the interaction established in humans or mainly theoretical? Is it dose-dependent? Does it affect a parent drug or active metabolite? Is the patient's indication compelling? Can a safer alternative achieve the same goal? Is monitoring feasible and timely? Could a recent symptom, laboratory change, or treatment failure be explained by the interaction? These questions help distinguish actionable warnings from low-value alerts [6, 10].

5.3 Prioritise severity, probability, and patient vulnerability

Severity refers to the potential consequence, such as life-threatening arrhythmia, major bleeding, respiratory depression, seizure, graft rejection, or loss of essential treatment. Probability reflects the strength of evidence and likelihood under the patient's circumstances. Vulnerability includes age, frailty, renal or hepatic impairment, pregnancy, electrolyte abnormalities, genetic variation, acute illness, and the presence of multiple prescribers. A high-severity interaction with a plausible mechanism deserves prompt attention even when the event is uncommon. Therapeutic index is particularly important. Warfarin, lithium, digoxin, selected antiepileptics, immunosuppressants, and some antiarrhythmics can require close monitoring when interacting medicines are started or stopped. Monitoring must be planned around the expected time course: a laboratory test obtained too early or too late may fail to detect a clinically important change [11].

5.4 Recognise clinical signals

Consider an interaction when a patient develops an unexplained adverse effect, a sudden change in a monitored laboratory value, or loss of response after a new medicine is added or removed. Examples include a rising international normalised ratio (INR), unexpected sedation, symptomatic hypotension, bradycardia, hypoglycaemia, acute kidney injury, electrolyte disturbance, or an unexpectedly low drug concentration. Establish timing, assess competing explanations, and treat urgent clinical problems first. Do not delay emergency management while trying to prove the interaction.

5.5 Use tools as aids, not substitutes

Resources may include current product information, institutional formularies, pharmacist consultation, clinical decision-support systems, therapeutic drug monitoring, and specialist databases. For older adults, the American Geriatrics Society Beers Criteria identify selected potentially inappropriate medicines and clinically important combinations, including opioid benzodiazepine use, multiple anticholinergics, and certain combinations that raise hyperkalaemia or bleeding risk [11]. Such criteria are screening aids, not automatic instructions to stop therapy; patient goals and clinical circumstances remain central [11-13].

Table 2. Structured questions for assessing a potential interaction.

Assessment question	What to establish	Why it matters
What is being taken?	Complete prescription, OTC, supplement, food, and alcohol history	Hidden exposure or duplicate therapy may be missed
What is the mechanism?	Absorption, enzyme/transporter, renal, or pharmacodynamic effect	Mechanism helps predict onset and appropriate mitigation
How serious is the outcome?	Bleeding, arrhythmia, respiratory depression, organ injury, treatment failure	Sets urgency and whether co-administration is acceptable
Who is at risk?	Age, frailty, pregnancy, renal/hepatic function, electrolytes, comorbidities	Patient factors can magnify an otherwise modest interaction
Can the plan be monitored?	Clinical signs, laboratory tests, drug levels, follow-up timing	Monitoring is only protective when feasible and acted upon

6. COMMON CLINICALLY IMPORTANT INTERACTIONS

The examples below are illustrative rather than exhaustive. Risk and recommended action vary with the exact medicine, dose, indication, organ function, and current product labelling. A combination should not be started, stopped, or adjusted solely on the basis of a general review article.

Table 3. Selected interactions that may require avoidance, adjustment, or monitoring [6,11].

Combination or context	Main concern	Practical response
Warfarin + selected antibiotics (e.g., trimethoprim–sulfamethoxazole) or amiodarone	INR elevation and bleeding risk	Avoid if a suitable alternative exists; if combined, arrange INR monitoring and clinician-directed dose adjustment
Anticoagulant + antiplatelet/NSAID	Bleeding, including gastrointestinal bleeding	Confirm indication for each agent; minimise duration and use gastroprotection when appropriate
Opioid + benzodiazepine or other sedative	Additive sedation and respiratory depression	Avoid where possible; if necessary, use the lowest effective doses, counsel and monitor closely
ACE inhibitor/ARB + potassium-sparing diuretic or potassium supplement	Hyperkalaemia, especially with kidney impairment	Review indication, renal function and potassium; repeat tests after initiation or dose changes
Lithium + NSAID, ACE inhibitor/ARB, or diuretic	Reduced lithium clearance and toxicity	Prefer alternatives where feasible; check lithium concentration, renal function and symptoms after changes
QT-prolonging medicines in combination	Torsades de pointes or other ventricular arrhythmia	Review cumulative risk, ECG, potassium and magnesium; avoid combinations in high-risk patients
Rifampicin + susceptible medicines	Reduced exposure and treatment failure	Check interaction-specific guidance; consider alternative treatment and plan for effects when rifampicin is stopped
Selected statins + strong CYP3A inhibitors	Myopathy or rhabdomyolysis	Select a less interaction-prone statin, adjust/hold according to product information, and assess muscle symptoms
Tetracycline/fluoroquinolone + iron, calcium, magnesium or aluminium	Reduced antibiotic absorption	Separate administration according to the specific product instructions
Multiple serotonergic medicines	Serotonin toxicity	Review necessity and dose; educate about agitation, sweating, tremor, clonus and fever; urgent assessment if suspected
Digoxin + selected P-gp inhibitors or medicines affecting renal function	Increased exposure and toxicity	Review dose, kidney function, heart rate, electrolytes and serum concentration when indicated
Insulin/sulfonylurea + agents that alter glucose control	Hypoglycaemia or loss of glycaemic control	Increase glucose monitoring during changes and individualise therapy



Figure 1. Overview of drug interaction mechanisms, clinical consequences, identification, prevention, and management in clinical practice.

6.1 Anticoagulants and medicines affecting haemostasis

Anticoagulants have substantial potential for harm when exposure increases or haemostasis is affected by another agent. Warfarin is especially susceptible to interactions involving metabolism, vitamin K availability, illness, and medicines that increase bleeding. Selected antibiotics, amiodarone, and some antidepressants may necessitate closer INR monitoring or a change in therapy. Direct oral anticoagulants also interact with certain P-gp and CYP3A inhibitors or inducers, although the magnitude differs among agents. NSAIDs and antiplatelet medicines can increase bleeding through effects on the gastrointestinal mucosa or platelet function even when anticoagulant concentrations do not change. Management begins by confirming the indication for every antithrombotic agent, avoiding unnecessary combinations, and arranging monitoring whenever an interacting drug is introduced or withdrawn [11].

6.2 Central nervous system depressants

Opioids, benzodiazepines, sedative hypnotics, gabapentinoids, alcohol, and other central nervous system depressants can produce additive sedation, impaired coordination, falls, and respiratory depression. Older adults and people with respiratory disease are particularly vulnerable. Concurrent use may occasionally be justified, but it should have a clear indication, a defined duration, and a plan for reassessment. Patients and caregivers should understand the warning signs of excessive sedation and when emergency help is needed. The AGS Beers Criteria advise avoiding selected high-risk combinations in older adults when possible [11].

6.3 Cardiovascular medicines and electrolyte disturbances

Cardiovascular interactions can affect blood pressure, heart rate, renal function, potassium, and cardiac repolarisation. Combining multiple agents that lower blood pressure may cause symptomatic hypotension, while combinations that slow atrioventricular conduction can produce bradycardia. Renin–angiotensin system inhibitors and potassium-sparing diuretics can increase potassium, especially in chronic kidney disease. Diuretics may also alter lithium concentrations or electrolytes relevant to arrhythmia risk. The response should be tailored to indication and baseline values, with repeat measurements after relevant changes.

6.4 QT prolongation and arrhythmia risk

QT prolongation is a pharmacodynamic hazard that may be amplified by combining susceptible medicines, hypokalaemia, hypomagnesaemia, bradycardia, congenital long-QT syndromes, or structural heart disease. An interaction checker should prompt a review of the complete regimen rather than only the newest prescription. In patients with meaningful risk, consider alternatives, obtain an ECG when indicated,

correct electrolytes, and reassess symptoms such as syncope or palpitations. A normal baseline ECG does not eliminate risk if new medicines or physiological changes occur.

6.5 Antimicrobials and treatment failure

Antimicrobials can inhibit or induce metabolism, alter QT intervals, affect anticoagulation, and interact through chelation or renal effects. Rifampicin is a prominent inducer, while selected macrolides and azole antifungals inhibit metabolic pathways. The consequences may include toxicity of a co-administered medicine or inadequate antimicrobial or companion-drug exposure. For medicines where treatment failure has serious consequences such as immunosuppressants, antiretrovirals, or selected antifungal regimens interaction review should occur before treatment begins and again when the interacting course ends.

6.6 Herbal products, supplements, and foods

Patients may not report herbal products because they regard them as natural or separate from treatment. St John's wort can induce enzymes and transporters and reduce exposure to several medicines. Grapefruit can inhibit intestinal CYP3A for susceptible substrates, while mineral supplements can bind selected antibiotics or thyroid hormone products. The effect depends on product composition, dose, preparation, and timing. Ask patients to bring containers or photographs when ingredients are unclear. Avoid broad claims that all supplements interact in the same way; use a product-specific reference and explain the reason for any restriction [1,6].

7. POPULATIONS REQUIRING ADDITIONAL ATTENTION

7.1 Older adults and polypharmacy

Older adults may experience changes in renal function, hepatic blood flow, body composition, and sensitivity to medicines. Multimorbidity and polypharmacy increase the number of possible interaction pairs, but the relationship is not purely numerical. Frailty, cognitive impairment, falls, limited monitoring, and use of multiple prescribers may further increase risk. A systematic review found substantial variation in reported interaction prevalence among community-dwelling older people, partly because studies used different screening tools and definitions [12]. This variability cautions against interpreting a single prevalence estimate as universal. Structured medication review should identify medicines without a current indication, duplicate therapies, prescribing cascades, and combinations whose risks outweigh benefits. Deprescribing should be planned with the patient and relevant prescribers, particularly when withdrawal effects or disease recurrence are possible. Beers Criteria and STOPP/START tools can support review but should not replace clinical reasoning [11,13].

7.2 Renal or hepatic impairment

Renal impairment may reduce elimination of parent drugs or active metabolites and amplify interactions involving kidney perfusion or electrolytes. Hepatic impairment can change metabolism, protein binding, and drug response. Assess kidney and liver function when clinically relevant, and use current dosing guidance rather than relying on a historical value. Acute dehydration, infection, or a newly added nephrotoxic drug can rapidly change risk. Therapeutic drug monitoring may be useful for selected agents, but interpretation requires correct timing and knowledge of the target range.

7.3 Pregnancy, lactation, and paediatrics

Pregnancy can change volume of distribution, renal clearance, and metabolic activity, while treatment decisions must also consider fetal risk and the consequences of untreated maternal disease. Lactation introduces a separate question about infant exposure. Children differ from adults in drug metabolism, body composition, and dosing requirements; adult interaction assumptions may not translate directly. These populations require age- or pregnancy-specific resources and specialist input when evidence is limited. Avoid abruptly discontinuing essential treatment without balancing maternal, fetal, infant, or paediatric risks.

7.4 Critical illness and transitions of care

In acute illness, rapidly changing renal function, hepatic perfusion, enteral feeding, vasopressors, and organ support can alter interaction risk. Intensive care patients may receive many medicines with narrow therapeutic windows and frequent changes. Admission, transfer, and discharge are also vulnerable points because medication lists may be incomplete or conflicting. A clear discharge list should distinguish medicines continued, started, changed, and stopped, and specify monitoring and follow-up responsibility.

8. PREVENTION STRATEGIES

8.1 Prescribing with an interaction-aware approach

Prevention begins before the prescription is written. Confirm the indication, expected benefit, duration, and whether a non-drug approach or a less interaction-prone medicine is appropriate. Consider the entire regimen rather than adding each medicine independently. Avoid unnecessary duplication, use the lowest effective dose for the appropriate duration, and reassess continued need. When a high-risk interaction is unavoidable, document why the combination is justified and how the risk will be controlled.

8.2 Medication reconciliation and structured review

A structured medication review should include the patient's goals, understanding, adherence, concerns, adverse effects, and all prescribed and non-prescribed products. Guidance recommends prioritising people taking multiple medicines, those with chronic conditions, and older adults when a clear purpose for review is identified [8]. The review should result in decisions: continue, stop, substitute, adjust, monitor, or seek specialist advice. Simply generating a list of potential interactions without action is unlikely to improve safety.

8.3 Laboratory and clinical monitoring

Monitoring should be specific to the expected harm. Examples include INR for warfarin, lithium concentrations and renal function for lithium, potassium and creatinine for renin–angiotensin system combinations, glucose for glucose-lowering therapy, ECG and electrolytes for selected QT-risk combinations, and drug concentrations for medicines where therapeutic monitoring is established. Specify the test, timing, responsible clinician, and action threshold. A monitoring plan without an assigned owner or follow-up mechanism is incomplete.

8.4 Patient and caregiver education

Counselling should be plain-language and actionable. Explain which combinations to avoid, whether doses need to be separated, what symptoms require urgent care, and whom to contact before starting an over-the-counter or herbal product. Encourage patients to maintain an updated medication list and share it with every healthcare professional. Use teach-back to confirm understanding, particularly for complex regimens or patients with limited health literacy. Avoid creating unnecessary fear: patients should not stop prescribed medicines on their own because a software alert or general warning appears.

8.5 Team-based prevention

Prescribers, pharmacists, nurses, specialists, and patients each hold part of the medication picture. Pharmacists can identify duplicate therapy, interpret interaction evidence, recommend alternatives, and organise monitoring. Nurses may identify early symptoms or administration issues. Prescribers must integrate the recommendation with the treatment goal and clinical status. Shared documentation and timely communication reduce the chance that a carefully designed plan is lost during handover.

Table 4. A practical prevention checklist [8,9].

Prevention step	Practical action	Documentation expected
Before prescribing	Confirm indication, medication list, organ function, allergies, and alternatives	Reason for treatment and interaction screening result
At initiation/change	Check severity, mechanism, dose, and onset; agree on mitigation	Decision to avoid, adjust, substitute, or co-administer
After initiation	Complete planned laboratory, ECG, symptom, or drug-level monitoring	Result, interpretation, and action taken
At transition	Reconcile the list and explain changes to patient and next provider	Updated list and named follow-up responsibility
At review	Assess continued need and deprescribe or simplify when appropriate	Shared decision and taper/monitoring plan if needed

9. MANAGEMENT WHEN AN INTERACTION IS IDENTIFIED OR SUSPECTED

9.1 Determine urgency and stabilise the patient

If there is evidence of a serious reaction—such as major bleeding, respiratory depression, severe hypotension, seizure, significant arrhythmia, or suspected serotonin toxicity stabilisation and emergency treatment take priority. Withhold or reverse a suspected causative medicine only in accordance with the clinical situation and relevant protocol; abrupt withdrawal of some therapies can also cause harm. Seek specialist or toxicology advice when the presentation is severe, the agent is unfamiliar, or antidote use is being considered.

9.2 Choose an appropriate management option

The options are not limited to stopping one medicine. They include avoiding the combination, selecting a therapeutic alternative, reducing or adjusting a dose, separating administration times when the mechanism supports it, limiting duration, increasing monitoring, or continuing both medicines with a documented rationale. Timing separation is useful for selected absorption interactions but does not solve enzyme inhibition, induction, or pharmacodynamic interactions. Dose adjustment must be based on interaction-specific evidence and the patient's clinical response rather than a generic percentage.

9.3 Monitor the response and reassess after discontinuation

When an interacting medicine is stopped, the risk does not always disappear immediately. Enzyme induction can persist while enzyme activity returns to baseline, and inhibition may continue according to the interacting drug's half-life and mechanism. A dose increased during an inducer course may become excessive when the inducer is withdrawn. Therefore, the plan should specify what happens both when the interaction begins and when it ends. Assess symptoms, laboratory results, therapeutic effect, and adherence, and revise the plan if the intended response is not achieved.

9.4 Document and report

Record the suspected interacting agents, likely mechanism, evidence, clinical consequence, action taken, monitoring plan, and communication with the patient and care team. Where an adverse drug reaction is suspected, report it through the applicable national or institutional pharmacovigilance system. Reporting can improve detection of uncommon interactions and support safer prescribing. Distinguish a confirmed interaction from a suspected association and document uncertainty honestly.



Figure 2. Stepwise clinical workflow for identifying and managing over routine drug interactions screening.

10. DIGITAL TOOLS, CLINICAL PHARMACISTS, AND DECISION SUPPORT

Electronic prescribing and interaction databases can improve access to information and help identify interactions at the point of care. Their effectiveness, however, depends on the quality of the underlying evidence, patient-specific data, interface design, and the actionability of alerts. Excessive low-value alerts can contribute to alert fatigue, encouraging users to override warnings without careful review. A systematic review of electronic drug-interaction alerts found limited evidence of improvement in patient-important outcomes and emphasised the need for better accuracy and patient-specific integration [14].

Decision-support systems should prioritise combinations with high likelihood and serious consequences, explain the mechanism, and suggest practical options. Useful alerts identify the affected

medicine, expected harm, relevant patient factors, and the recommended response. Systems should support documentation of a justified override and avoid repeatedly presenting the same non-actionable warning. Local formularies and institutional protocols should be updated as evidence and product information change. Clinical pharmacists contribute by performing medication reconciliation, evaluating interaction evidence, recommending alternatives, advising on dose adjustment and monitoring, and counselling patients. Their contribution is particularly valuable for complex regimens, narrow-therapeutic-index medicines, high-risk transitions, and patients with renal impairment or multiple prescribers. Collaborative practice works best when roles and follow-up responsibilities are explicit. Pharmacogenomic information may explain some variation in metabolism or response, but genotype alone does not predict every interaction. A potent enzyme inhibitor can cause phenoconversion, making the functional metabolic state differ from what genotype alone suggests. Pharmacogenomics should therefore be used when supported by drug-specific evidence and interpreted alongside clinical factors, co-medications, and monitoring [15].

11. CHALLENGES AND FUTURE DIRECTIONS

Several challenges remain. First, interaction databases differ in severity grading and may present inconsistent recommendations. Second, many potential interactions have limited direct clinical-outcome evidence, while patients with multimorbidity are underrepresented in some studies. Third, complex regimens can produce multidrug interactions that are not adequately captured by pairwise screening. Fourth, incomplete records of non-prescription products and care received outside a health system undermine accurate assessment. Finally, monitoring recommendations may be impractical if tests, appointments, or specialist advice are not readily available.

Future work should improve the clinical validation of interaction alerts, incorporate patient-specific variables, and measure outcomes that matter to patients, including preventable adverse events, treatment failure, hospitalisation, and quality of life. Interoperable medication records could improve reconciliation across settings. Better research is also needed on interactions in pregnancy, paediatrics, frailty, and patients taking complex combinations. Implementation studies should evaluate not only whether an alert changes prescribing but whether the intervention reduces harm without causing undertreatment or unnecessary discontinuation.

Artificial intelligence and predictive analytics may help prioritise complex regimens, but they must be transparent, validated, and integrated into clinician workflows. Automated recommendations should identify the source of evidence and the limits of confidence. Human oversight remains essential because an apparently risky combination may be necessary for a particular patient, and an alternative may be less effective or carry its own harms. [10,14].

12. PRACTICAL CLINICAL RECOMMENDATIONS

- Maintain an accurate medication list that includes non-prescription medicines, supplements, and relevant foods or alcohol.
- Check interactions when medicines are started, stopped, or changed—not only at the first prescription.
- Prioritise interactions that may cause severe harm, treatment failure, or toxicity in a narrow-therapeutic-index medicine.
- Interpret software alerts using the exact drug, dose, formulation, patient factors, and current product information.
- Prefer avoidance or substitution when a serious interaction has a safer alternative; use dose adjustment or monitoring only when supported by evidence.
- Specify monitoring tests, timing, responsibility, and follow-up actions before the interacting regimen begins.
- Explain the plan to patients and caregivers and advise them to consult a clinician before adding OTC or herbal products.
- Review the interaction plan again when the interacting medicine is discontinued, because enzyme effects and altered doses may persist.
- Document decisions, justified overrides, counselling, and adverse-event reports.
- Use multidisciplinary medication review to reduce unnecessary polypharmacy and improve continuity at transitions of care.

CONCLUSION

Drug interactions are common, diverse, and not uniformly harmful. Their clinical importance

depends on the mechanism, magnitude, evidence, therapeutic index, patient vulnerability, and ability to monitor or mitigate risk. A reliable approach combines comprehensive medication reconciliation, verification with current resources, patient-specific risk assessment, appropriate selection of avoidance or mitigation strategies, and planned follow-up. High-risk examples involving anticoagulants, central nervous system depressants, electrolyte-altering medicines, QT-prolonging agents, enzyme modulators, and narrow-therapeutic-index drugs deserve particular attention. Digital tools can support clinical judgement but should not replace it. Pharmacists and multidisciplinary teams can improve prevention and management through structured review, counselling, monitoring, and communication. Embedding these practices in routine prescribing and transitions of care can reduce avoidable medication-related harm while preserving the benefits of necessary combination therapy.

DECLARATIONS

Funding: No specific funding was received for this narrative review.

Conflict of interest: The author declares no conflict of interest.

Ethical approval: Not applicable; this narrative review did not involve human participants.

Acknowledgement

The author gratefully acknowledges the curators and indexing teams of PubMed, MEDLINE, Embase, Google Scholar, the Cochrane Library, the Directory of Open Access Journals (DOAJ), and BMJ Clinical Evidence. Their platforms and commitment to open-access research were vital in identifying the primary studies, clinical trials, narrative and systematic reviews that informed this article.

REFERENCES

1. Lynch SS. Drug interactions. Merck Manual Professional Edition. Reviewed March 2025. Available from: https://www.merckmanuals.com/professional/clinical-pharmacology/factors-affecting-response-to-medications/drug-interactions.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19. doi:10.1136/bmj.329.7456.15.
3. Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533-544. doi:10.1586/17512433.2014.910111.
4. World Health Organization. Medication without harm: policy brief. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240062764.
5. Specialist Pharmacy Service. Understanding drug interactions. Published January 15, 2024; updated May 22, 2024. Available from: https://sps.nhs.uk/articles/understanding-drug-interactions/.
6. US Food and Drug Administration. FDA's examples of drugs that interact with CYP enzymes and transporter systems: for healthcare professionals. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
7. US Food and Drug Administration. M12 Drug Interaction Studies. Final guidance. Silver Spring (MD): FDA; August 2024. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies.
8. National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guideline NG5. London: NICE; 2015. Available from: https://www.nice.org.uk/guidance/ng5/chapter/Recommendations.
9. Killin L, Hezam A, Anderson KK, Welk B. Advanced medication reconciliation: a systematic review of the impact on medication errors and adverse drug events associated with transitions of care. Jt Comm J Qual Patient Saf. 2021;47(7):438-451. doi:10.1016/j.jcjq.2021.03.011.
10. Ryu JY, Kim HU, Lee SY. Deep learning improves prediction of drug-drug and drug-food interactions. Proc Natl Acad Sci U S A. 2018;115(18):E4304-E4311. doi:10.1073/pnas.1803294115.
11. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372.
12. Hughes JE, Waldron C, Bennett KE, Cahir C. Prevalence of drug-drug interactions in older community-dwelling individuals: a systematic review and meta-analysis. Drugs Aging. 2023;40(2):117-134.

doi:10.1007/s40266-022-01001-5.

13. O'Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14:625-632. doi:10.1007/s41999-023-00777-y.
14. Holbrook AM, Matos Silva J, Faruque JAY, Deng J, Schneider T, Jaffer A. Effect of electronic drug-drug interaction alerts on patient and clinician outcomes: a systematic review. J Am Med Inform Assoc. 2025;32(10):1617-1628. doi:10.1093/jamia/ocaf139.
15. Turgeon J, Michaud V, Steffen J, et al. Multidrug interactions: why do they occur and how to handle? Clin Pharmacol Ther. 2023. PMID: 36682993. Available from: https://pubmed.ncbi.nlm.nih.gov/36682993